Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Targeting metabolic circuitry to supercharge CD8+ T cell antitumor responses

Targeting metabolism to enhance immunotherapy within tumor microenvironment

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Regulation of CD8+ T cells by lipid metabolism in cancer progression

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment

Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity

Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy

Metabolic reprogramming of antitumor CD8+ T cells by modulation of GSH-Gpx4 axis

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

Metabolic interventions: A new insight into the cancer immunotherapy

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells

Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness

Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors